on January 14, 2019, the Court entered the Confirmation Order confirming the Plan under Chapter 11 of the Bankruptcy Code. On the Effective Date, and substantially concurrent with the consummation of the Iroko Acquisition, the Plan became effective. Pursuant to the Plan, a new board of directors of the Egalet Corporation took office as of the Effective Date, consisting of: Robert S. Radie; Andrea Heslin Smiley; Timothy P. Walbert (collectively with Mr. Radie and Ms. Smiley, the ‘Continuing Directors’); Joseph McInnis; Luke Düster; Todd Holmes; and Matthew Pauls. Upon the effectiveness of the Plan, on the Effective Date, the following members of the Company’s prior board of directors were deemed to have resigned as directors of the Company: Elaine Hochberg; Nicholas C. Nicolaides; John E. Osborn; Robert P. Roche, Jr.; John Varian; and Gregory Weaver. Joseph McInnis, is a Principal at Murrin Construction. Prior to joining Murrin Construction, Mr. McInnis served as Managing Director and Investment Analyst at Greywolf Capital from 2004 to 2015 and as an Investment Analyst in Goldman Sachs’ Special Situations Investing Group from 2001 to 2004. Mr. McInnis currently serves on the boards of Aspire Oil & Gas and the Washington Mutual Inc. Liquidating Trust, positions he has held since November 2015. Luke Düster is a member of the Founders Group at CRG. Prior to CRG, Mr. Düster was an investment banker at Harris Williams & Co. Todd Holmes serves as a Principal at CRG. Prior to joining CRG, Todd was an investor and founding member of Gurnet Point Capital. Matthew Pauls has served as Chief Executive Officer of Strongbridge Biopharma plc since August 2014 and as a member of its board of directors since September 2015. Mr. Pauls has served as a member of the board of directors of Savara Inc. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed Inc.